SCHEMBL2896442

SCHEMBL2896442

CCN(CC)CCOc1ccc(C(CO)(Cc2ccc(OC)cc2)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.54
HTT P42858 2/20 0.54
CYP1A2 P05177 1/20 0.54
LTA4H P09960 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
EBP Q15125 4/20 0.53
SIGMAR1 Q99720 4/20 0.53
MMP1 P03956 1/20 0.49
MMP9 P14780 1/20 0.49
MMP13 P45452 1/20 0.49
MCHR1 Q99705 5/20 0.48
ESR1 P03372 4/20 0.46
KCNH2 Q12809 3/20 0.46
CHRM2 P08172 2/20 0.46
ADRA2A P08913 2/20 0.46
ADORA3 P0DMS8 2/20 0.46
CHRM1 P11229 2/20 0.46
PTGS1 P23219 2/20 0.46
SLC6A2 P23975 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330094 0.88 SIGMAR1 (0.67) CYP2D6HTTCYP1A2LTA4HCYP2C9
SCHEMBL16910242 0.81 SIGMAR1 (0.69) CYP2D6HTTCYP1A2LTA4HCYP2C9
SCHEMBL3294808 0.80 CYP2D6 (0.54) CYP2D6HTTCYP1A2LTA4HCYP2C9
Citric Acid SCHEMBL17164694 0.79 KDM4E (0.59) CYP2D6HTTCYP1A2LTA4HCYP2C9
SCHEMBL8707174 0.78 EBP (0.56) CYP2D6HTTCYP1A2LTA4HCYP2C9
SCHEMBL7753432 0.75 SIGMAR1 (0.79) CYP2D6HTTCYP1A2LTA4HCYP2C9
SCHEMBL6769894 0.75 CYP2D6 (0.48) CYP2D6HTTCYP1A2LTA4HCYP2C9
SCHEMBL4310502 0.74 EBP (0.81) CYP2D6HTTCYP1A2LTA4HCYP2C9
SCHEMBL1379752 0.74 LTA4H (0.57) HTTLTA4HSIGMAR1MMP1MMP13
SCHEMBL10356744 0.74 CYP2D6 (0.58) CYP2D6HTTCYP1A2LTA4HCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515424-A1 ANTIESTROGENS AND/OR AROMATASE INHIBITORS FOR USE IN TREATING OBESITY AND RELATED SYMPTOMS Repros Therapeutics Inc. (US) 2019-07-31 EP disclosed
WO-2018058032-A1 ANTIESTROGENS AND/OR AROMATASE INHIBITORS FOR USE IN TREATING OBESITY AND RELATED SYMPTOMS REPROS THERAPEUTICS INC. (US) 2018-03-29 WO disclosed
EP-2914294-A1 TRANS-CLOMIPHENE FOR USE IN CANCER THERAPY Repros Therapeutics Inc. (US) 2015-09-09 EP disclosed
EP-2819676-A1 COMBINATION THERAPY FOR TREATING ANDROGEN DEFICIENCY Repros Therapeutics Inc. (US) 2015-01-07 EP disclosed
WO-2014070523-A1 TRANS-CLOMIPHENE FOR USE IN CANCER THERAPY REPROS THERAPEUTICS INC. (US) 2014-05-08 WO disclosed
WO-2013130832-A1 COMBINATION THERAPY FOR TREATING ANDROGEN DEFICIENCY REPROS THERAPEUTICS INC. (US) 2013-09-06 WO disclosed
EP-2211848-A1 TRANS-CLOMIPHENE FOR METABOLIC SYNDROME Repros Therapeutics Inc. (US) 2010-08-04 EP disclosed
WO-2010054248-A1 TRANS-CLOMIPHENE FOR METABOLIC SYNDROME AND DIABETES MELLITUS TYPE 2 REPROS THERAPEUTICS INC. (US) 2010-05-14 WO disclosed
WO-2009051908-A1 TRANS-CLOMIPHENE FOR METABOLIC SYNDROME REPROS THERAPEUTICS INC. (US) 2009-04-23 WO disclosed